Tinzaparin (Innohep)
Other Medications · Approved since 2000
Description
Tinzaparin is a low molecular weight heparin (LMWH) anticoagulant used for venous thromboembolism prophylaxis in colorectal cancer patients. In CRC treatment, it serves as supportive care to prevent blood clots during the perioperative period and in patients with metastatic disease who have increased thrombotic risk. Clinical trials have evaluated extended perioperative tinzaparin administration to potentially improve disease-free survival outcomes in resectable colorectal cancer patients.
Mechanism of Action
Tinzaparin binds to antithrombin III, forming a complex that inhibits activated factor X (factor Xa) and thrombin, with preferential anti-factor Xa activity. This mechanism prevents the formation of fibrin clots by interrupting the coagulation cascade at multiple points. The anticoagulant effect helps reduce the risk of venous thromboembolism, which is elevated in cancer patients due to tumor-induced hypercoagulable states.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Innohep |
| Category | Other Medications |
 Status | FDA Approved |
 EMA Status | EMA Approved |
 Spain Access | Funded by SNS other indication |
| Administration | Subcutaneous |
| Year Approved | 2000 |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.